Loading data for HOWL — first visit, this takes a few seconds.

提醒

Werewolf Therapeutics Inc... (HOWL)

NasdaqCM: HOWL · 即時價格 · USD

0.97

-0.02 (-2.02%)

收盤價： Aug 27, 2026, 3:59 PM

0.93

-4.15%

盤前: 5:32 AM

股價、關鍵數字和最新消息，都在這一頁。

-2.02% (1D)

買價	0.87
市值	47.18M
營收 (ttm)	21M
淨利（ttm）	-34.61M
	0.29
	-0.71
	n/a
	-1.65
P/B (ttm)	2.90
P/S (ttm)	2.25
財報日期	Oct 30, 2026

賣價	1.2
成交量	2,193,513
20 日平均成交量	6,808,682
開盤價	0.99
前收盤價	0.99
當日區間	0.91 - 1.00
52 週範圍	0.27 - 2.38
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 HOWL

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead prod...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Apr 30, 2021

員工 39

證券交易所 NasdaqCM

股票代號 HOWL

網站 https://werewolftx.com

完整的公司簡介

財務表現

Werewolf Therapeutics 在 2025 年的營收為 0，較前一年的 1.89M 減少 -100%。淨利為 -60.82M，較前期減少 -13.75%。

財務報表

財報驚奇

Werewolf Therapeutics 已於 Jul 31, 2026 公布季度財報：

營收為 $21M 低於預期 $0, 年增 Infinity% 成長.
每股盈餘為 0.14 超出預期 0.46, 年增 135.00% 成長.

下次財報發布

Werewolf Therapeutics Inc. 的下次財報預計於 Oct 30, 2026, 開盤前。
分析師預估營收 ... 升級

新聞動態

6 天前 · Barchart

Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News

Werewolf Therapeutics stock explodes higher on a merger agreement with Ambros Therapeutics. But is there any further upside left in HOWL shares?

6 天前 · MT Newswires

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S

1 週前 · InvestorsHub

Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing

Werewolf Therapeutics Inc (NASDAQ:HOWL) shares soared 120% in premarket trading on Friday after the biotechnology company agreed to merge with Ambros Therapeutics Inc alongside a $150 million private ...

3 週前 · Zacks

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.

3 月前 · Simply Wall St.

Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

第 1 頁，共 2 頁

Werewolf Therapeutics Inc... (HOWL)